The Validation Trap

There is a sentence I have heard more times than I can count in regulated environments:

“We need to validate this before we can move forward."

In regulated industries, validation is not optional. Healthcare, pharmaceuticals, finance, aviation, and critical infrastructure all rely on rigorous processes designed to ensure that systems are safe, reliable, and fit for purpose. Those safeguards exist for good reasons and they can be the only thing standing between a useful innovation and a very expensive mistake.

Yet somewhere along the way, many organizations developed a curious habit of using validation to avoid responsibility.

The organizations that speak most passionately about rigor are not always the ones managing risk most effectively. Sometimes they are simply very good at delaying decisions, reaching a state where validation stops being a mechanism for learning and becomes a mechanism for preventing action.

What Validation Is Supposed To Do

Before criticizing validation, it’s worth acknowledging why it exists.

The original purpose of validation in clinical environments is straightforward: before a system influences a consequential decision, you need evidence that it behaves reliably under the conditions where it will be used. Validation emerged because “trust me” is not a quality system.

This is reasonable. Healthcare decisions carry asymmetric consequences. A single failure can cause irreversible harm. The argument for caution before deployment is not bureaucratic timidity. It is a rational response to a real asymmetry. The frameworks served a genuine function.

The history of modern quality management is, in many ways, a history of learning that assumptions are not enough. Validation is one of the reasons complex systems work as reliably as they do. The problem is what happens when validation is no longer connected to decision-making.

The goal is not certainty. The goal is sufficient confidence. This distinction matters because certainty is usually impossible. No clinical trial proves a drug will work for every patient. No software test guarantees the absence of bugs. No security audit demonstrates that a system can never be compromised.

Validation has always been about managing uncertainty, not eliminating it.

When Validation Becomes a Waiting Room

In practice, validation processes rarely remain neutral mechanisms. They accumulate institutional mass. They acquire stakeholders. They develop a lifecycle that is increasingly disconnected from the original engineering or scientific question they were created to answer.

I have seen this repeatedly. A method would clear every technical bar that had been specified in advance. Controls behaved as expected. Reproducibility held across conditions. External comparisons were favorable. And yet, the process did not conclude.

New requirements appeared. Additional datasets were requested. Edge cases were introduced that had not been part of the original scope. Each addition was individually defensible. Collectively, they formed something different: a system that could not reach a decision.

This is the validation trap.

It does not announce itself. It rarely involves explicit obstruction. It operates through the entirely legitimate mechanism of asking for more evidence, indefinitely.

Every real-world decision is made under incomplete information. A hospital adopting a new workflow does not know exactly how clinicians will use it. A pharmaceutical company implementing a new analytics platform does not know every future use case. An organization deploying an AI assistant does not know every edge case that will emerge.

No amount of pre-deployment testing can fully answer questions that only arise after deployment.

At some point, the organization must decide.

Medicine Never Waited For Perfect Knowledge

One of the most interesting aspects of this discussion is that medicine itself has never operated on the assumption that uncertainty must disappear before action is taken.

Take paracetamol.

It is one of the most widely used medications in the world. It has been administered billions of times and remains a cornerstone of everyday clinical practice. Yet despite decades of use, the precise mechanisms underlying its therapeutic effects are still not fully understood.

At the same time, we understand its risks extremely well. We know that overdoses can cause severe liver toxicity. We know how to identify patients at risk. We know how to monitor for complications. We know when intervention is required.

Medicine did not wait for perfect mechanistic understanding before making paracetamol available.

Instead, it built governance around uncertainty.

The critical question was never whether uncertainty existed. The critical question was whether the benefits outweighed the risks under defined conditions, and whether appropriate safeguards existed to manage those risks.

That distinction matters because it points toward a more productive way of thinking about AI.

The goal should not be to prove that an AI system can never fail. No complex system can satisfy that standard. The goal should be to establish guardrails, monitoring mechanisms, escalation pathways, and operational oversight that allow failures to be detected and managed when they occur.

In pharmaceuticals, we call this pharmacovigilance.

The equivalent concept for AI is still emerging, but the principle is the same.

Mature systems are not built on certainty. They are built on governance.

The trap has two faces

The first face is institutional.

Organizations that have historically been exposed to risk from premature adoption develop cultures where caution is rewarded and speed is penalized. This is an understandable adaptation. It is also one that generalizes badly.

A culture calibrated for managing pharmaceutical approvals does not transfer cleanly to managing software deployment timelines. The consequence asymmetries are different. The reversibility of failure is different. Yet the cultural response is often identical because institutions do not easily distinguish between categories of risk.

The second face is individual.

Institutions reward the avoidance of visible failures far more consistently than they reward the creation of invisible benefits. No committee member is criticized for requesting additional evidence. Many have been criticized for approving something that later failed.

The incentive structure is therefore predictable. More validation is always defensible. Approval always carries personal exposure.

The result is a system where perpetual validation becomes the dominant equilibrium.

This is where validation can become something else entirely. Not a governance mechanism. Not a quality process. A performance.

Validation theater occurs when the primary function of validation is no longer to generate information but to demonstrate caution. In the worst cases, the objective is no longer to determine whether a system should be deployed. The objective becomes ensuring that nobody can later be blamed for deploying it.

Governance Is Not A Downstream Step

One of the most persistent structural errors in healthcare AI development is treating governance as something that follows technical completion. Build the system. Validate the system. Then figure out how it will be governed. No pharmaceutical product would ever reach the market under that logic.

Long before approval, there is already a clear understanding of how safety events will be reported, monitored, escalated, and acted upon. Governance is not something that happens after deployment. It is part of what makes deployment possible.

The same principle applies to AI.

By the time teams arrive at the governance question, they have often already made hundreds of decisions that constrain what governance is possible. Data provenance, model updates, logging architecture, auditability, escalation pathways, and human oversight are not separate from the system. From the perspective of anyone responsible for authorization, they are the system.

Organizations that successfully navigate deployment do not design governance after technical completion. They design governance alongside technical development. They identify the questions decision-makers will eventually need answered and begin generating evidence against those questions from the beginning. They treat the path to authorization as a product requirement rather than a post-launch concern.

The Last Mile Is Not A Technical Problem

I have watched technically sound systems spend years in validation processes that were, in practice, indeterminate. The teams involved were not incompetent. The organizations were not malicious. The systems themselves were genuinely useful.

But there was no defined condition under which validation would conclude. No clear owner of the decision. No explicit threshold that, once crossed, would result in deployment.

There was only the ongoing possibility of asking for more.

The irony is that healthcare professionals make difficult decisions under uncertainty every day. Physicians routinely balance incomplete information, competing risks, and imperfect evidence. A surgeon does not wait until all uncertainty disappears before entering the operating room. At some point, sufficient evidence has been gathered and a decision must be made because the risks of inaction have become greater than the risks of action.

Organizations often struggle with precisely this step.

They become exceptionally good at evaluating the risks of change while becoming remarkably poor at evaluating the risks of delay.

The underlying mistake is subtle. Organizations often compare the risks of a proposed system against an idealized future state rather than against the imperfect system that exists today. The relevant comparison is not between a new system and perfection. It is between a new system and the current alternative.

The status quo receives an implicit exemption from scrutiny simply because it already exists.

The Real Cost Of The Trap

The validation trap is rarely perceived as a failure mode from inside the institution. From inside, it looks like rigor. That is what makes it durable.

The cost is largely invisible because it is denominated in things that never happened: systems never deployed, workflows never improved, decisions never better supported, opportunities never realized.

Unlike a failed deployment, a perpetually deferred one produces no incident report. It triggers no retrospective. It simply persists.

There is also a second-order cost that compounds over time. Teams that spend years navigating indefinite evaluation processes learn to optimize for evaluation rather than for use. The incentive drifts toward producing evidence that satisfies validation criteria rather than building systems that function effectively in practice.

Clinical environments eventually end up with systems that are exceptionally well documented and operationally inert.

The greatest danger is not that validation exists. It is that validation becomes detached from decision-making. Once that happens, evidence is no longer being collected to inform a choice. It is being collected to postpone one.

The question is not whether uncertainty remains. The question is whether enough has been learned to justify a decision.

Expertise And The Responsibility To Decide

Experienced clinicians do not wait until uncertainty disappears before acting.

They build internal models of reality that allow them to act despite uncertainty. They learn which unknowns matter, which unknowns do not, and when additional information is likely to change a decision.

That ability is one of the defining characteristics of expertise.

The same principle applies to organizations.

Mature organizations do not eliminate uncertainty before deploying systems. They develop enough understanding of the system, the risks, the benefits, and the safeguards to make an informed decision and accept responsibility for it.

The validation trap begins when validation becomes a substitute for judgment. Because at that point evidence is no longer being gathered to support a decision. It is being gathered to avoid making one. And the paradox is that institutions can become so focused on avoiding the risks of deployment that they fail to notice the risks accumulating from delay.

The safest decision is not always the one that waits longest.

Sometimes the greatest risk is the belief that more validation will eventually remove the need to decide.